JLE

Virologie

MENU

Progrès récents dans la compréhension et le diagnostic de l’infection chronique par le virus de l’hépatite B Volume 23, numéro 1, Janvier-Février 2019

  • [1] Seto W.K., Lo Y.R., Pawlotsky J.M., Yuen M.F. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324.
  • [2] Ginzberg D., Wong R.J., Gish R. Global HBV burden : guesstimates and facts. Hepatol Int. 2018;12:315-329.
  • [3] Graber-Stiehl I. The silent epidemic killing more people than HIV, malaria or TB. Nature. 2018;564:24-26.
  • [4] Stanaway J.D., Flaxman A.D., Naghavi M., Fitzmaurice C., Vos T., Abubakar I. The global burden of viral hepatitis from 1990 to 2013 : findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081-1088.
  • [5] Cohen J. Forgotten no more. Science. 2018;362:984-987.
  • [6] Schweitzer A., Horn J., Mikolajczyk R.T., Krause G., Ott J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection : a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555.
  • [7] Lai C.L., Ratziu V., Yuen M.F., Poynard T. Viral hepatitis B. Lancet. 2003;362:2089-2094.
  • [8] Bertoletti A., Tan A.T., Gehring A.J. HBV-Specific Adaptive Immunity. Viruses. 2009;1:91-103.
  • [9] Busca A., Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014;11:22.
  • [10] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017 ; 67 : 370-398.
  • [11] Allweiss L., Dandri M. Experimental in vitro and in vivo models for the study of human hepatitis B virus infection. J Hepatol. 2016;64:S17-31.
  • [12] Yan H., Zhong G., Xu G., He W., Jing Z., Gao Z., Huang Y. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.
  • [13] Ni Y., Lempp F.A., Mehrle S., Nkongolo S., Kaufman C., Falth M., Stindt J. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070-1083.
  • [14] Wedemeyer H., Bogomolov P., Blank A., Allweiss L., Dandri-Petersen M., Bremer B., Voronkova N. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection. J Hepatol. 2018;68:S3. S1
  • [15] Li W., Urban S. Entry of hepatitis B and hepatitis D virus into hepatocytes : Basic insights and clinical implications. J Hepatol. 2016;64:S32-40.
  • [16] Nassal M. HBV cccDNA : viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64:1972-1984.
  • [17] Koniger C., Wingert I., Marsmann M., Rosler C., Beck J., Nassal M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A. 2014;111:E4244-4253.
  • [18] Qi Y., Gao Z., Xu G., Peng B., Liu C., Yan H., Yao Q. DNA Polymerase kappa Is a Key Cellular Factor for the Formation of Covalently Closed Circular DNA of Hepatitis B Virus. PLoS Pathog. 2016;12:e1005893.
  • [19] Kitamura K., Que L., Shimadu M., Koura M., Ishihara Y., Wakae K., Nakamura T. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathog. 2018;14:e1007124.
  • [20] Belloni L., Pollicino T., De Nicola F., Guerrieri F., Raffa G., Fanciulli M., Raimondo G. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009;106:19975-19979.
  • [21] Blank A., Eidam A., Haag M., Hohmann N., Burhenne J., Schwab M., van de Graaf S. The NTCP-inhibitor Myrcludex B : Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. Clin Pharmacol Ther. 2018;103:341-348.
  • [22] Schinazi R.F., Ehteshami M., Bassit L., Asselah T. Towards HBV curative therapies. Liver Int. 2018;38 Suppl 1:102-114.
  • [23] Lanford RE, Guerra B, Chavez D, Giavedoni L, Hodara VL, Brasky KM, Fosdick A, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013 ; 144 : 1508-1517, 1517 e1501-1510.
  • [24] Suresh M., Korolowicz K.E., Balarezo M., Iyer R.P., Padmanabhan S., Cleary D., Gimi R. Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. PLoS One. 2017;12:e0169631.
  • [25] Lok A.S., Pan C.Q., Han S.H., Trinh H.N., Fessel W.J., Rodell T., Massetto B. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65:509-516.
  • [26] Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology. 2014;57:141-150.
  • [27] Raimondi S., Maisonneuve P., Bruno S., Mondelli M.U. Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol. 2010;52:441-449.
  • [28] Mason W.S., Gill U.S., Litwin S., Zhou Y., Peri S., Pop O., Hong M.L. HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. Gastroenterology. 2016;151:986-998 e984.
  • [29] Fourati S., Challine D., Poveda J.D., Laperche S., Rallier S., Pawlotsky J.M., Chevaliez S. Evaluation of a new random-access HBV DNA molecular assay : The VERIS HBV assay. J Clin Virol. 2017;92:69-74.
  • [30] Fourati S., Pawlotsky J.M. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016;5. 10.12688/f1000research.8983.1
  • [31] Chevaliez S., Challine D., Naija H., Luu T.C., Laperche S., Nadala L., Allain J.P. Performance of a new rapid test for the detection of hepatitis B surface antigen in various patient populations. J Clin Virol. 2014;59:89-93.
  • [32] Servant-Delmas A., Ly T.D., Hamon C., Houdah A.K., Laperche S. Comparative Performance of Three Rapid HBsAg Assays for Detection of HBs Diagnostic Escape Mutants in Clinical Samples. J Clin Microbiol. 2015;53:3954-3955.
  • [33] Amini A., Varsaneux O., Kelly H., Tang W., Chen W., Boeras D.I., Falconer J. Diagnostic accuracy of tests to detect hepatitis B surface antigen : a systematic review of the literature and meta-analysis. BMC Infect Dis. 2017;17:698.
  • [34] Robin L., Mboumba Bouassa R.S., Nodjikouambaye Z.A., Charmant L., Matta M., Simon S., Filali M. Analytical performances of simultaneous detection of HIV-1, HIV-2 and hepatitis C- specific antibodies and hepatitis B surface antigen (HBsAg) by multiplex immunochromatographic rapid test with serum samples : A cross-sectional study. J Virol Methods. 2018;253:1-4.
  • [35] Boyd A., Lacombe K., Lavocat F., Maylin S., Miailhes P., Lascoux-Combe C., Delaugerre C. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J Hepatol. 2016;65:683-691.
  • [36] Lai C.L., Wong D., Ip P., Kopaniszen M., Seto W.K., Fung J., Huang F.Y. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J Hepatol. 2017;66:275-281.
  • [37] Levrero M., Pollicino T., Petersen J., Belloni L., Raimondo G., Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51:581-592.
  • [38] Lucifora J., Protzer U. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol. 2016;64:S41-S48.
  • [39] Bill C.A., Summers J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration. Proc Natl Acad Sci U S A. 2004;101:11135-11140.
  • [40] Yang W., Summers J. Illegitimate replication of linear hepadnavirus DNA through nonhomologous recombination. J Virol. 1995;69:4029-4036.
  • [41] Gong S.S., Jensen A.D., Wang H., Rogler C.E. Duck hepatitis B virus integrations in LMH chicken hepatoma cells : identification and characterization of new episomally derived integrations. J Virol. 1995;69:8102-8108.
  • [42] Zoulim F., Testoni B., Lebosse F. Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B : lessons from experimental and clinical studies. Clin Gastroenterol Hepatol. 2013;11:1011-1013.
  • [43] Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., Romagnoli V. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology. 2010;139:483-490.
  • [44] Chevaliez S. Is HBsAg quantification ready, for prime time? Clin Res Hepatol Gastroenterol. 2013;37:559-563.
  • [45] Invernizzi F., Vigano M., Grossi G., Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36 Suppl 1:100-104.
  • [46] Manno M., Camma C., Schepis F., Bassi F., Gelmini R., Giannini F., Miselli F. Natural history of chronic HBV carriers in northern Italy : morbidity and mortality after 30 years. Gastroenterology. 2004;127:756-763.
  • [47] Zacharakis G.H., Koskinas J., Kotsiou S., Papoutselis M., Tzara F., Vafeiadis N., Archimandritis A.J. Natural history of chronic HBV infection : a cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project). J Med Virol. 2005;77:173-179.
  • [48] Martinot-Peignoux M., Lapalus M., Asselah T., Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int. 2013;33:125-132. Suppl 1
  • [49] Brouwer W.P., Chan H.L., Brunetto M.R., Martinot-Peignoux M., Arends P., Cornberg M., Cherubini B. Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. Clin Gastroenterol Hepatol. 2016;14:1481-9e5. 10.1016/j.cgh.2016.01.019
  • [50] Pfefferkorn M., Bohm S., Schott T., Deichsel D., Bremer C.M., Schroder K., Gerlich W.H. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut. 2018;67:2045-2053.
  • [51] Ma H., Yang R.F., Wei L. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients. J Gastroenterol Hepatol. 2010;25:1498-1506.
  • [52] Chan H.L. Response-guided therapy by hepatitis B surface antigen level for peginterferon therapy : what is next? J Gastroenterol Hepatol. 2012;27:420-421.
  • [53] Sonneveld M.J., Hansen B.E., Piratvisuth T., Jia J.D., Zeuzem S., Gane E., Liaw Y.F. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872-880.
  • [54] Chevaliez S., Hezode C., Bahrami S., Grare M., Pawlotsky J.M. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy : finite treatment duration unlikely. J Hepatol. 2013;58:676-683.
  • [55] Luckenbaugh L., Kitrinos K.M., Delaney W.E.t., Hu J. Genome-free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy. J Viral Hepat. 2015;22:561-570.
  • [56] Wang J., Shen T., Huang X., Kumar G.R., Chen X., Zeng Z., Zhang R. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65:700-710.
  • [57] Wong D.K., Seto W.K., Cheung K.S., Chong C.K., Huang F.Y., Fung J., Lai C.L. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37:995-1001.
  • [58] Honda M., Shirasaki T., Terashima T., Kawaguchi K., Nakamura M., Oishi N., Wang X. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis. 2016;213:1096-1106.
  • [59] Wong D.K., Tanaka Y., Lai C.L., Mizokami M., Fung J., Yuen M.F. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942-3947.
  • [60] Suzuki F., Miyakoshi H., Kobayashi M., Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27-33.
  • [61] Chen E.Q., Feng S., Wang M.L., Liang L.B., Zhou L.Y., Du L.Y., Yan L.B. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173.
  • [62] Seto W.K., Wong D.K., Fung J., Huang F.Y., Liu K.S., Lai C.L., Yuen M.F. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014;20:1173-1180.
  • [63] Maasoumy B., Wiegand S.B., Jaroszewicz J., Bremer B., Lehmann P., Deterding K., Taranta A. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect. 2015;21:606 e1-10.
  • [64] Riveiro-Barciela M., Bes M., Rodriguez-Frias F., Tabernero D., Ruiz A., Casillas R., Vidal-Gonzalez J. Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus genotype. Clin Microbiol Infect. 2017;23:860-867.
  • [65] Okuhara S., Umemura T., Joshita S., Shibata S., Kimura T., Morita S., Komatsu M. Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B. Hepatol Res. 2014;44:E172-180.
  • [66] Wang B., Carey I., Bruce M., Montague S., Dusheiko G., Agarwal K. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. J Viral Hepat. 2018;25:886-893.
  • [67] Jung K.S., Park J.Y., Chon Y.E., Kim H.S., Kang W., Kim B.K., Kim S.U. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol. 2016;51:830-839.
  • [68] Matsumoto A., Nishiguchi S., Enomoto H., Kang J.H., Tanaka Y., Shinkai N., Kurosaki M. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol. 2018;53:247-257.
  • [69] Tada T., Kumada T., Toyoda H., Kiriyama S., Tanikawa M., Hisanaga Y., Kanamori A. HBcrAg predicts hepatocellular carcinoma development : An analysis using time-dependent receiver operating characteristics. J Hepatol. 2016;65:48-56.
  • [70] Kumada T., Toyoda H., Tada T., Kiriyama S., Tanikawa M., Hisanaga Y., Kanamori A. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients : a propensity score analysis. J Hepatol. 2013;58:427-433.
  • [71] Hosaka T., Suzuki F., Kobayashi M., Hirakawa M., Kawamura Y., Yatsuji H., Sezaki H. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int. 2010;30:1461-1470.
  • [72] Seto W.K., Wong D.K., Chan T.S., Hwang Y.Y., Fung J., Liu K.S., Gill H. Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. Am J Gastroenterol. 2016;111:1788-1795.
  • [73] Kock J., Theilmann L., Galle P., Schlicht H.J. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology. 1996;23:405-413.
  • [74] Giersch K., Allweiss L., Volz T., Dandri M., Lutgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66:460-462.
  • [75] Wang J., Du M., Huang H., Chen R., Niu J., Jiang J., Zhuang H. Reply to : “Serum HBV pgRNA as a clinical marker for cccDNA activity” : Consistent loss of serum HBV RNA might predict the “para-functional cure” of chronic hepatitis B. J Hepatol. 2017;66:462-463.
  • [76] van Bömmel F. The level of HBV RNA in serum as a novel marker for the phase of chronic hepatitis B virus (HBV) infections. In : American Association for the Study of Liver Diseases 2016 ; 2016. Présentation no 1814.
  • [77] van Bömmel F., van Bommel A., Krauel A., Wat C., Pavlovic V., Yang L., Deichsel D. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. J Infect Dis. 2018;218:1066-1074.
  • [78] van Bömmel F., Bartens A., Mysickova A., Hofmann J., Kruger D.H., Berg T., Edelmann A. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66-76.
  • [79] van Campenhout M.J.H., van Bommel F., Pfefferkorn M., Fischer J., Deichsel D., Boonstra A., van Vuuren A.J. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology. 2018;68:839-847.